InDex Pharmaceuticals Holding AB
STO:FLERIE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Salesforce Inc
NYSE:CRM
|
Technology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| UK |
|
Endava PLC
NYSE:DAVA
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Citigroup Inc
NYSE:C
|
Banking
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
| US |
|
Fortinet Inc
NASDAQ:FTNT
|
Technology
|
| US |
|
Intel Corp
NASDAQ:INTC
|
Semiconductors
|
| US |
|
Starbucks Corp
NASDAQ:SBUX
|
Hotels, Restaurants & Leisure
|
| US |
|
Copart Inc
NASDAQ:CPRT
|
Commercial Services & Supplies
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8.8
55.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Salesforce Inc
NYSE:CRM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Endava PLC
NYSE:DAVA
|
UK |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Citigroup Inc
NYSE:C
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
|
Fortinet Inc
NASDAQ:FTNT
|
US |
|
|
Intel Corp
NASDAQ:INTC
|
US |
|
|
Starbucks Corp
NASDAQ:SBUX
|
US |
|
|
Copart Inc
NASDAQ:CPRT
|
US |
This alert will be permanently deleted.
InDex Pharmaceuticals Holding AB
Cash Equivalents
InDex Pharmaceuticals Holding AB
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Cash Equivalents
kr911.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Cash Equivalents
kr2.8B
|
CAGR 3-Years
86%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Cash Equivalents
kr170m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Cash Equivalents
kr111.3m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Cash Equivalents
kr60.6m
|
CAGR 3-Years
46%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InDex Pharmaceuticals Holding AB
Glance View
InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
See Also
What is InDex Pharmaceuticals Holding AB's Cash Equivalents?
Cash Equivalents
911.3m
SEK
Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Cash Equivalents amounts to 911.3m SEK.
What is InDex Pharmaceuticals Holding AB's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
51%
Over the last year, the Cash Equivalents growth was 151%. The average annual Cash Equivalents growth rates for InDex Pharmaceuticals Holding AB have been 25% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
